Tilray Brands, Inc. (TLRY.TO)

Negative net income growth while Drug Manufacturers - Specialty & Generic median is -11.74%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.

D&A growth of 10.12% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.

Deferred tax shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.

SBC declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.

Working capital of 49.04% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.

AR shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage in working capital if sales do not drop.

Inventory shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a working capital edge if sales hold up.

Growth of 172.84% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.

Under 50% of Drug Manufacturers - Specialty & Generic median of 10.65% if negative or well above if positive. Jim Chanos would flag potential major accounting illusions or revaluations overshadowing underlying performance.

CapEx declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.

Acquisition growth of 128.89% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or partial deals fueling that difference.

No Data available this quarter, please select a different quarter.

We reduce “other investing” yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a potential advantage in preserving cash if top-line growth is not harmed.

Reduced investing yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.

Debt repayment yoy declines while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.

We reduce yoy buybacks while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees a potential missed chance unless expansions promise higher returns.